The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine
•Response to escitalopram was associated with higher baseline serotonin levels.•Response to escitalopram was associated with lower baseline Kyn/Trp ratio and quinolinic acid (QuinA)/tryptophan (Trp) ratio.•Remitters to escitalopram showed significant increases in KynA/3HK ratio. The response of pati...
Saved in:
| Published in: | Brain, behavior, and immunity Vol. 87; pp. 404 - 412 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Netherlands
Elsevier Inc
01.07.2020
|
| Subjects: | |
| ISSN: | 0889-1591, 1090-2139, 1090-2139 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | •Response to escitalopram was associated with higher baseline serotonin levels.•Response to escitalopram was associated with lower baseline Kyn/Trp ratio and quinolinic acid (QuinA)/tryptophan (Trp) ratio.•Remitters to escitalopram showed significant increases in KynA/3HK ratio.
The response of patients with major depressive disorders (MDD) to antidepressant treatments have been shown to be affected by multiple factors, including disease severity and inflammation. Increasing evidence indicates that the kynurenine metabolic pathway is activated by inflammation in MDD patients and plays a role in the pathophysiology of depression. Antidepressant treatments have been reported to affect kynurenine pathway metabolite levels as well. This study investigates differential associations between the antidepressant treatment outcome to escitalopram versus desvenlafaxine with the pre-treatment and post-treatment-changes in serotonin and kynurenine pathway metabolite levels.
The levels of serotonin and of kynurenine pathway metabolites were measured in plasma using liquid chromatography-mass spectrometry (LC-MS) in 161 currently depressed patients with MDD at baseline and after 8 weeks of treatment with either escitalopram or desvenlafaxine. Treatment response was defined conventionally by a reduction of at least 50% in the Hamilton Depression Rating Scale 21 item (HAMD-21) total score from baseline; remission was defined by reaching a post-treatment HAMD-21 score ≤7.
Response to escitalopram treatment was associated with higher baseline serotonin levels (p = 0.022), lower baseline kynurenine (Kyn)/tryptophan (Trp) ratio (p = 0.008) and lower baseline quinolinic acid (QuinA)/tryptophan (Trp) ratio (p = 0.047), suggesting a lower inflammation state. Greater improvement in depression symptoms as measured by percent change of HAMD-21 score from baseline was also associated with higher baseline serotonin levels (p = 0.033) in escitalopram treatment arm. Furthermore, remitters to escitalopram treatment showed significant increases in the kynurenic acid (KynA)/3-hydroxykynurenine (3HK) ratio after treatment (p = 0.015). In contrast, response to desvenlafaxine treatment was not associated with any metabolite analyzed. We also confirmed a previous report that plasma serotonin levels are lower in MDD patients compared to healthy controls (p = 0.004) and that the kynurenine plasma level is negatively associated with depression symptom severity (p = 0.047).
In MDD patients the antidepressant response to escitalopram was positively associated with baseline serotonin levels and inversely associated with activation of the kynurenine pathway. These results appear consistent with previous literature showing that biomarker evidence of inflammation is associated with lower response to antidepressants from the selective serotonin reuptake inhibitor class. Moreover, increases in the kynurenic acid (KynA)/3-hydroxykynurenine (3HK) ratio, which previously has been characterized as a neuroprotective index, were associated with full remission under escitalopram treatment. |
|---|---|
| AbstractList | The response of patients with major depressive disorders (MDD) to antidepressant treatments have been shown to be affected by multiple factors, including disease severity and inflammation. Increasing evidence indicates that the kynurenine metabolic pathway is activated by inflammation in MDD patients and plays a role in the pathophysiology of depression. Antidepressant treatments have been reported to affect kynurenine pathway metabolite levels as well. This study investigates differential associations between the antidepressant treatment outcome to escitalopram versus desvenlafaxine with the pre-treatment and post-treatment-changes in serotonin and kynurenine pathway metabolite levels.INTRODUCTIONThe response of patients with major depressive disorders (MDD) to antidepressant treatments have been shown to be affected by multiple factors, including disease severity and inflammation. Increasing evidence indicates that the kynurenine metabolic pathway is activated by inflammation in MDD patients and plays a role in the pathophysiology of depression. Antidepressant treatments have been reported to affect kynurenine pathway metabolite levels as well. This study investigates differential associations between the antidepressant treatment outcome to escitalopram versus desvenlafaxine with the pre-treatment and post-treatment-changes in serotonin and kynurenine pathway metabolite levels.The levels of serotonin and of kynurenine pathway metabolites were measured in plasma using liquid chromatography-mass spectrometry (LC-MS) in 161 currently depressed patients with MDD at baseline and after 8 weeks of treatment with either escitalopram or desvenlafaxine. Treatment response was defined conventionally by a reduction of at least 50% in the Hamilton Depression Rating Scale 21 item (HAMD-21) total score from baseline; remission was defined by reaching a post-treatment HAMD-21 score ≤7.METHODSThe levels of serotonin and of kynurenine pathway metabolites were measured in plasma using liquid chromatography-mass spectrometry (LC-MS) in 161 currently depressed patients with MDD at baseline and after 8 weeks of treatment with either escitalopram or desvenlafaxine. Treatment response was defined conventionally by a reduction of at least 50% in the Hamilton Depression Rating Scale 21 item (HAMD-21) total score from baseline; remission was defined by reaching a post-treatment HAMD-21 score ≤7.Response to escitalopram treatment was associated with higher baseline serotonin levels (p = 0.022), lower baseline kynurenine (Kyn)/tryptophan (Trp) ratio (p = 0.008) and lower baseline quinolinic acid (QuinA)/tryptophan (Trp) ratio (p = 0.047), suggesting a lower inflammation state. Greater improvement in depression symptoms as measured by percent change of HAMD-21 score from baseline was also associated with higher baseline serotonin levels (p = 0.033) in escitalopram treatment arm. Furthermore, remitters to escitalopram treatment showed significant increases in the kynurenic acid (KynA)/3-hydroxykynurenine (3HK) ratio after treatment (p = 0.015). In contrast, response to desvenlafaxine treatment was not associated with any metabolite analyzed. We also confirmed a previous report that plasma serotonin levels are lower in MDD patients compared to healthy controls (p = 0.004) and that the kynurenine plasma level is negatively associated with depression symptom severity (p = 0.047).RESULTSResponse to escitalopram treatment was associated with higher baseline serotonin levels (p = 0.022), lower baseline kynurenine (Kyn)/tryptophan (Trp) ratio (p = 0.008) and lower baseline quinolinic acid (QuinA)/tryptophan (Trp) ratio (p = 0.047), suggesting a lower inflammation state. Greater improvement in depression symptoms as measured by percent change of HAMD-21 score from baseline was also associated with higher baseline serotonin levels (p = 0.033) in escitalopram treatment arm. Furthermore, remitters to escitalopram treatment showed significant increases in the kynurenic acid (KynA)/3-hydroxykynurenine (3HK) ratio after treatment (p = 0.015). In contrast, response to desvenlafaxine treatment was not associated with any metabolite analyzed. We also confirmed a previous report that plasma serotonin levels are lower in MDD patients compared to healthy controls (p = 0.004) and that the kynurenine plasma level is negatively associated with depression symptom severity (p = 0.047).In MDD patients the antidepressant response to escitalopram was positively associated with baseline serotonin levels and inversely associated with activation of the kynurenine pathway. These results appear consistent with previous literature showing that biomarker evidence of inflammation is associated with lower response to antidepressants from the selective serotonin reuptake inhibitor class. Moreover, increases in the kynurenic acid (KynA)/3-hydroxykynurenine (3HK) ratio, which previously has been characterized as a neuroprotective index, were associated with full remission under escitalopram treatment.CONCLUSIONSIn MDD patients the antidepressant response to escitalopram was positively associated with baseline serotonin levels and inversely associated with activation of the kynurenine pathway. These results appear consistent with previous literature showing that biomarker evidence of inflammation is associated with lower response to antidepressants from the selective serotonin reuptake inhibitor class. Moreover, increases in the kynurenic acid (KynA)/3-hydroxykynurenine (3HK) ratio, which previously has been characterized as a neuroprotective index, were associated with full remission under escitalopram treatment. •Response to escitalopram was associated with higher baseline serotonin levels.•Response to escitalopram was associated with lower baseline Kyn/Trp ratio and quinolinic acid (QuinA)/tryptophan (Trp) ratio.•Remitters to escitalopram showed significant increases in KynA/3HK ratio. The response of patients with major depressive disorders (MDD) to antidepressant treatments have been shown to be affected by multiple factors, including disease severity and inflammation. Increasing evidence indicates that the kynurenine metabolic pathway is activated by inflammation in MDD patients and plays a role in the pathophysiology of depression. Antidepressant treatments have been reported to affect kynurenine pathway metabolite levels as well. This study investigates differential associations between the antidepressant treatment outcome to escitalopram versus desvenlafaxine with the pre-treatment and post-treatment-changes in serotonin and kynurenine pathway metabolite levels. The levels of serotonin and of kynurenine pathway metabolites were measured in plasma using liquid chromatography-mass spectrometry (LC-MS) in 161 currently depressed patients with MDD at baseline and after 8 weeks of treatment with either escitalopram or desvenlafaxine. Treatment response was defined conventionally by a reduction of at least 50% in the Hamilton Depression Rating Scale 21 item (HAMD-21) total score from baseline; remission was defined by reaching a post-treatment HAMD-21 score ≤7. Response to escitalopram treatment was associated with higher baseline serotonin levels (p = 0.022), lower baseline kynurenine (Kyn)/tryptophan (Trp) ratio (p = 0.008) and lower baseline quinolinic acid (QuinA)/tryptophan (Trp) ratio (p = 0.047), suggesting a lower inflammation state. Greater improvement in depression symptoms as measured by percent change of HAMD-21 score from baseline was also associated with higher baseline serotonin levels (p = 0.033) in escitalopram treatment arm. Furthermore, remitters to escitalopram treatment showed significant increases in the kynurenic acid (KynA)/3-hydroxykynurenine (3HK) ratio after treatment (p = 0.015). In contrast, response to desvenlafaxine treatment was not associated with any metabolite analyzed. We also confirmed a previous report that plasma serotonin levels are lower in MDD patients compared to healthy controls (p = 0.004) and that the kynurenine plasma level is negatively associated with depression symptom severity (p = 0.047). In MDD patients the antidepressant response to escitalopram was positively associated with baseline serotonin levels and inversely associated with activation of the kynurenine pathway. These results appear consistent with previous literature showing that biomarker evidence of inflammation is associated with lower response to antidepressants from the selective serotonin reuptake inhibitor class. Moreover, increases in the kynurenic acid (KynA)/3-hydroxykynurenine (3HK) ratio, which previously has been characterized as a neuroprotective index, were associated with full remission under escitalopram treatment. The response of patients with major depressive disorders (MDD) to antidepressant treatments have been shown to be affected by multiple factors, including disease severity and inflammation. Increasing evidence indicates that the kynurenine metabolic pathway is activated by inflammation in MDD patients and plays a role in the pathophysiology of depression. Antidepressant treatments have been reported to affect kynurenine pathway metabolite levels as well. This study investigates differential associations between the antidepressant treatment outcome to escitalopram versus desvenlafaxine with the pre-treatment and post-treatment-changes in serotonin and kynurenine pathway metabolite levels. The levels of serotonin and of kynurenine pathway metabolites were measured in plasma using liquid chromatography-mass spectrometry (LC-MS) in 161 currently depressed patients with MDD at baseline and after 8 weeks of treatment with either escitalopram or desvenlafaxine. Treatment response was defined conventionally by a reduction of at least 50% in the Hamilton Depression Rating Scale 21 item (HAMD-21) total score from baseline; remission was defined by reaching a post-treatment HAMD-21 score ≤7. Response to escitalopram treatment was associated with higher baseline serotonin levels (p = 0.022), lower baseline kynurenine (Kyn)/tryptophan (Trp) ratio (p = 0.008) and lower baseline quinolinic acid (QuinA)/tryptophan (Trp) ratio (p = 0.047), suggesting a lower inflammation state. Greater improvement in depression symptoms as measured by percent change of HAMD-21 score from baseline was also associated with higher baseline serotonin levels (p = 0.033) in escitalopram treatment arm. Furthermore, remitters to escitalopram treatment showed significant increases in the kynurenic acid (KynA)/3-hydroxykynurenine (3HK) ratio after treatment (p = 0.015). In contrast, response to desvenlafaxine treatment was not associated with any metabolite analyzed. We also confirmed a previous report that plasma serotonin levels are lower in MDD patients compared to healthy controls (p = 0.004) and that the kynurenine plasma level is negatively associated with depression symptom severity (p = 0.047). In MDD patients the antidepressant response to escitalopram was positively associated with baseline serotonin levels and inversely associated with activation of the kynurenine pathway. These results appear consistent with previous literature showing that biomarker evidence of inflammation is associated with lower response to antidepressants from the selective serotonin reuptake inhibitor class. Moreover, increases in the kynurenic acid (KynA)/3-hydroxykynurenine (3HK) ratio, which previously has been characterized as a neuroprotective index, were associated with full remission under escitalopram treatment. |
| Author | Sun, Yu Li, Qingqin S. Turecki, Gustavo Drevets, Wayne |
| Author_xml | – sequence: 1 givenname: Yu surname: Sun fullname: Sun, Yu organization: Neuroscience, Janssen R&D, LLC, United States – sequence: 2 givenname: Wayne surname: Drevets fullname: Drevets, Wayne organization: Neuroscience, Janssen R&D, LLC, United States – sequence: 3 givenname: Gustavo surname: Turecki fullname: Turecki, Gustavo organization: McGill Group for Suicide Studies (MGSS), Douglas Mental Health University Institute, Frank B. Common (FBC) F-3145, 6875 LaSalle Boulevard, Montreal (Quebec) H4H 1R3, Canada – sequence: 4 givenname: Qingqin S. surname: Li fullname: Li, Qingqin S. email: qli2@its.jnj.com organization: Neuroscience, Janssen R&D, LLC, United States |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31978524$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkc9qGzEQxkVJaZy0D9BL0bGXdTW7Xq-WnkroPwj0kp7FrHaE5WilrSQ78Vv0kSvHySWHFAaEhu_3DfPNBTvzwRNj70EsQcD603Y5DHZZi1osBZSCV2wBohdVDU1_xhZCyr6CtodzdpHSVgjRNiDfsPMG-k629WrB_t5siEdymG3waWNnPlC-I_J8dpgm5IliyMFbz9GP_Pbgd5HKj_iMeXOHBz5RxiE4m4k72pNLD8JcbHMkzBP5XAakudiXVuCUtM3owhxxepCOlPbkHRq8L75v2WuDLtG7x_eS_f729ebqR3X96_vPqy_XlW6hzlVZapAoa2H6ttYIQPUayGjqjFwPbbeSa9kAmIYkmtE02PWlNYjeaOgK21yyjyffOYY_O0pZTTZpcg49hV1SdbNqW9FKsS7SD4_S3TDRqOZoJ4wH9ZRiEXQngY4hpUhGHVc8JpojWqdAqOO91FaVe6njvZSAUlBIeEY-mb_EfD4xJWvaW4qqJEpe02gj6azGYF-k-2e0dtZbje6WDv9h_wHeFcO6 |
| CitedBy_id | crossref_primary_10_3168_jds_2020_19222 crossref_primary_10_3389_fphar_2022_984383 crossref_primary_10_1016_j_tem_2024_07_014 crossref_primary_10_1038_s41380_020_00940_y crossref_primary_10_3390_ph15091054 crossref_primary_10_3390_jcm11092517 crossref_primary_10_1016_j_ejphar_2024_176434 crossref_primary_10_3389_fphar_2021_799561 crossref_primary_10_1016_j_bbi_2021_03_022 crossref_primary_10_1016_j_neuroscience_2022_06_024 crossref_primary_10_1097_MCO_0000000000001077 crossref_primary_10_3389_fimmu_2021_716980 crossref_primary_10_1039_D0FO02855J crossref_primary_10_1007_s00213_025_06841_8 crossref_primary_10_3390_ijms24032231 crossref_primary_10_3390_cells12232749 crossref_primary_10_1016_j_jpba_2023_115304 crossref_primary_10_2147_JIR_S436907 crossref_primary_10_1007_s12035_025_05210_y crossref_primary_10_1016_j_bbi_2025_05_025 crossref_primary_10_3390_cells10061548 crossref_primary_10_3390_cells13020177 crossref_primary_10_1016_j_neubiorev_2021_09_023 crossref_primary_10_1016_j_jagp_2022_08_004 crossref_primary_10_1111_pcn_13373 crossref_primary_10_1016_j_bbih_2020_100167 crossref_primary_10_1002_prp2_1217 crossref_primary_10_1186_s12916_024_03248_8 crossref_primary_10_1016_j_euroneuro_2020_11_016 crossref_primary_10_1016_j_pnpbp_2024_111031 crossref_primary_10_1038_s41398_024_02992_y crossref_primary_10_1038_s41598_022_22744_6 crossref_primary_10_1016_j_neuropharm_2020_108174 crossref_primary_10_1186_s12872_023_03378_6 crossref_primary_10_1016_j_pnpbp_2022_110608 crossref_primary_10_3389_fpsyt_2024_1357293 crossref_primary_10_1016_j_mehy_2023_111120 crossref_primary_10_1038_s41598_020_73918_z crossref_primary_10_1177_02698811241249651 crossref_primary_10_1016_j_jad_2025_01_064 crossref_primary_10_1016_j_psyneuen_2021_105273 crossref_primary_10_3389_fpsyt_2024_1380620 crossref_primary_10_1080_15622975_2023_2169348 crossref_primary_10_1016_j_biopha_2025_118093 crossref_primary_10_1016_j_bbih_2022_100537 crossref_primary_10_1016_j_jad_2023_07_078 |
| Cites_doi | 10.1016/j.neubiorev.2010.06.006 10.1016/j.jpsychires.2015.05.007 10.1016/S0049-3848(99)00015-8 10.1016/j.psyneuen.2017.01.023 10.1097/01.jcp.0000161500.58266.90 10.1016/j.tips.2012.09.006 10.1016/0304-3940(93)90752-7 10.1093/ijnp/pyw045 10.1007/s00702-011-0668-8 10.1016/j.bbi.2012.06.001 10.1111/acps.12698 10.1038/npp.2011.132 10.3389/fcvm.2017.00048 10.1176/appi.ajp.2014.14010094 10.1016/j.jchromb.2019.02.021 10.2741/s518 10.1176/appi.ajp.158.11.1843 10.1016/j.biopsych.2012.12.007 10.1038/s41398-017-0056-8 10.1016/j.biopsych.2008.08.010 10.1007/978-3-319-70178-3_5 10.1176/ajp.2006.163.11.1905 10.1016/j.biopsych.2009.09.033 10.3109/13651501.2015.1031139 10.1016/j.bbi.2015.06.001 10.1016/j.biopsych.2018.12.020 10.1038/tp.2011.22 10.1016/j.jad.2006.07.013 10.1146/annurev-clinpsy-050212-185606 10.1126/science.1078197 10.1016/j.psyneuen.2010.09.012 10.1016/j.psyneuen.2014.11.015 10.1097/00004850-199311002-00006 10.1371/journal.pone.0197268 10.1016/j.jpsychires.2015.04.026 10.1038/npp.2014.194 10.1016/j.euroneuro.2012.09.009 10.1002/syn.22021 10.1001/archpsyc.1991.01810330075011 10.1038/npp.2012.191 10.1038/npp.2016.143 10.1016/j.jpsychires.2019.03.013 10.4088/JCP.14m09298 10.1016/j.ejphar.2014.02.012 10.1016/j.jad.2011.08.003 10.1016/j.bbr.2019.112041 10.1097/PSY.0b013e3181907c1b 10.1016/j.pnpbp.2017.04.026 10.1046/j.1460-9568.1999.00806.x 10.1038/mp.2016.6 |
| ContentType | Journal Article |
| Copyright | 2020 Janssen Research & Development, LLC Copyright © 2020 Janssen Research & Development, LLC. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2020 Janssen Research & Development, LLC – notice: Copyright © 2020 Janssen Research & Development, LLC. Published by Elsevier Inc. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.bbi.2020.01.011 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1090-2139 |
| EndPage | 412 |
| ExternalDocumentID | 31978524 10_1016_j_bbi_2020_01_011 S0889159119306622 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 23N 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 8P~ 9JM 9JO AAAJQ AADFP AAEDT AAEDW AAGJA AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXLA AAXUO AAYWO ABCQJ ABFNM ABFRF ABIVO ABJNI ABMAC ABOYX ABWVN ABXDB ACDAQ ACGFO ACGFS ACLOT ACRLP ACRPL ACVFH ACXNI ADBBV ADCNI ADEZE ADFGL ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGEKW AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CAG CJTIS COF CS3 DM4 DU5 EBS EFBJH EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMG HMQ HVGLF HZ~ IHE J1W KOM L7B LG5 LUGTX LZ5 M2U M41 MO0 MOBAO N9A O-L O9- OAUVE OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SCC SDF SDG SDP SES SEW SIN SNS SPCBC SSB SSI SSN SSY SSZ T5K TN5 UAP UNMZH UPT WUQ XPP XSW Z5R ZGI ZMT ~G- ~HD ~S- 6I. AACTN AADPK AAFTH AAIAV ABYKQ AFKWA AFYLN AJBFU AJOXV AMFUW RIG 9DU AAYXX CITATION AFCTW AGCQF AGRNS BNPGV CGR CUY CVF ECM EIF NPM SSH 7X8 |
| ID | FETCH-LOGICAL-c512t-591b8a820f952ca11e261efce7f86b574868311f3e8afdf3a79486b09fc1791b3 |
| ISICitedReferencesCount | 48 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000542965400093&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0889-1591 1090-2139 |
| IngestDate | Thu Oct 02 19:37:36 EDT 2025 Mon Jul 21 05:56:32 EDT 2025 Sat Nov 29 07:19:28 EST 2025 Tue Nov 18 21:02:52 EST 2025 Fri Feb 23 02:43:14 EST 2024 Tue Oct 14 19:24:29 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2020 Janssen Research & Development, LLC. Published by Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c512t-591b8a820f952ca11e261efce7f86b574868311f3e8afdf3a79486b09fc1791b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.clinicalkey.com/#!/content/1-s2.0-S0889159119306622 |
| PMID | 31978524 |
| PQID | 2345505806 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_2345505806 pubmed_primary_31978524 crossref_citationtrail_10_1016_j_bbi_2020_01_011 crossref_primary_10_1016_j_bbi_2020_01_011 elsevier_sciencedirect_doi_10_1016_j_bbi_2020_01_011 elsevier_clinicalkey_doi_10_1016_j_bbi_2020_01_011 |
| PublicationCentury | 2000 |
| PublicationDate | July 2020 2020-07-00 20200701 |
| PublicationDateYYYYMMDD | 2020-07-01 |
| PublicationDate_xml | – month: 07 year: 2020 text: July 2020 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Brain, behavior, and immunity |
| PublicationTitleAlternate | Brain Behav Immun |
| PublicationYear | 2020 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Cattaneo, Gennarelli, Uher, Breen, Farmer, Aitchison, Craig, Anacker, Zunsztain, McGuffin, Pariante (b0020) 2013; 38 Cattaneo, Ferrari, Uher, Bocchio-Chiavetto, Riva, Consortium, Pariante (b0015) 2016; 19 Jha, Minhajuddin, Gadad, Greer, Grannemann, Soyombo, Mayes, Rush, Trivedi (b0115) 2017; 78 Reus, Jansen, Titus, Carvalho, Gabbay, Quevedo (b0190) 2015 Block, Kunkel, Schwarz (b0010) 1993; 149 Nie, Vairavan, Narayan, Ye, Li (b0165) 2018; 13 Higashino, Ago, Umehara, Kita, Fujita, Takuma, Matsuda (b0095) 2014; 729 Jha, Minhajuddin, Chin-Fatt, Greer, Carmody, Trivedi (b0110) 2019; 113 Coccurello (b0025) 2019; 372 Felger, Treadway (b0040) 2017; 42 Liu, Ray, Neavin, Zhang, Athreya, Biernacka, Bobo, Hall-Flavin, Skime, Zhu, Jenkins, Batzler, Kalari, Boakye-Agyeman, Matson, Bhasin, Mushiroda, Nakamura, Kubo, Iyer, Wang, Frye, Kaddurah-Daouk, Weinshilboum (b0140) 2018; 8 Hannestad, DellaGioia, Bloch (b0085) 2011; 36 Rush, Trivedi, Wisniewski, Nierenberg, Stewart, Warden, Niederehe, Thase, Lavori, Lebowitz, McGrath, Rosenbaum, Sackeim, Kupfer, Luther, Fava (b0195) 2006; 163 Zhu, Bogdanov, Boyle, Matson, Sharma, Matson, Churchill, Fiehn, Rush, Krishnan, Pickering, Delnomdedieu, Kaddurah-Daouk, Pharmacometabolomics Research (b0260) 2013; 8 Gold, Blum, Febo, Baron, Modestino, Elman, Badgaiyan (b0055) 2018; 10 Kocki, Wnuk, Kloc, Kocki, Owe-Larsson, Urbanska (b0125) 2012; 119 Howren, Lamkin, Suls (b0105) 2009; 71 Frank, Prien, Jarrett, Keller, Kupfer, Lavori, Rush, Weissman (b0045) 1991; 48 Perlis (b0170) 2013; 74 Gupta, Neavin, Liu, Biernacka, Hall-Flavin, Bobo, Frye, Skime, Jenkins, Batzler, Kalari, Matson, Bhasin, Zhu, Mushiroda, Nakamura, Kubo, Wang, Kaddurah-Daouk, Weinshilboum (b0070) 2016; 21 Pizzagalli (b0175) 2014; 10 Halaris, Myint, Savant, Meresh, Lim, Guillemin, Hoppensteadt, Fareed, Sinacore (b0080) 2015; 66–67 Wiedlocha, Marcinowicz, Krupa, Janoska-Jazdzik, Janus, Debowska, Mosiolek, Waszkiewicz, Szulc (b0250) 2018; 80 Treadway, Zald (b0225) 2011; 35 Walther, Peter, Bashammakh, Hortnagl, Voits, Fink, Bader (b0240) 2003; 299 Liu, Ho, Mak (b0145) 2012; 139 Dowlati, Herrmann, Swardfager, Liu, Sham, Reim, Lanctot (b0035) 2010; 67 Frankle, Robertson, Maier, Paris, Asmonga, May, Himes, Mason, Mathis, Narendran (b0050) 2018; 72 Raison, Borisov, Majer, Drake, Pagnoni, Woolwine, Vogt, Massung, Miller (b0185) 2009; 65 Kohler, Freitas, Maes, de Andrade, Liu, Fernandes, Stubbs, Solmi, Veronese, Herrmann, Raison, Miller, Lanctot, Carvalho (b0130) 2017; 135 Wang, Zhang, Tao, Zhou, Liu, Pan, Liao, Chang (b0245) 2019; 1112 Blardi, de Lalla, Urso, Auteri, Dell'Erba, Bossini, Castrogiovanni (b0005) 2005; 25 Herr, Bode, Duerschmied (b0090) 2017; 4 Kaddurah-Daouk, Boyle, Matson, Sharma, Matson, Zhu, Bogdanov, Churchill, Krishnan, Rush, Pickering, Delnomdedieu (b0120) 2011; 1 Thase (b0220) 2001; 7 Hiles, Baker, de Malmanche, Attia (b0100) 2012; 26 Salomon, Miller, Delgado, Charney (b0200) 1993; 8 Yee, Chin, Hashim, Harbajan Singh, Loh, Sulaiman, Ng (b0255) 2015; 19 Lamers, Milaneschi, Smit, Schoevers, Wittenberg, Penninx (b0135) 2019; 85 Uher, Tansey, Dew, Maier, Mors, Hauser, Dernovsek, Henigsberg, Souery, Farmer, McGuffin (b0230) 2014; 171 Greenberg, Fournier, Sisitsky, Pike, Kessler (b0060) 2015; 76 Myint, Kim, Verkerk, Scharpe, Steinbusch, Leonard (b0160) 2007; 98 Meyer, Wilson, Ginovart, Goulding, Hussey, Hood, Houle (b0155) 2001; 158 Guidetti, Schwarcz (b0065) 1999; 11 Powell, Schalkwyk, Heffernan, Breen, Lawrence, Price, Farmer, Aitchison, Craig, Danese, Lewis, McGuffin, Uher, Tansey, D'Souza (b0180) 2013; 23 Savitz, Dantzer, Wurfel, Victor, Ford, Bodurka, Bellgowan, Teague, Drevets (b0205) 2015; 52 Savitz, Drevets, Smith, Victor, Wurfel, Bellgowan, Bodurka, Teague, Dantzer (b0210) 2015; 40 Stone, Stoy, Darlington (b0215) 2013; 34 Varghese, Griffin, Singer (b0235) 2017; 1043 McNicol, Israels (b0150) 1999; 95 Dantzer, O'Connor, Lawson, Kelley (b0030) 2011; 36 Haapakoski, Mathieu, Ebmeier, Alenius, Kivimaki (b0075) 2015; 49 Myint (10.1016/j.bbi.2020.01.011_b0160) 2007; 98 Yee (10.1016/j.bbi.2020.01.011_b0255) 2015; 19 Hannestad (10.1016/j.bbi.2020.01.011_b0085) 2011; 36 Cattaneo (10.1016/j.bbi.2020.01.011_b0020) 2013; 38 Dowlati (10.1016/j.bbi.2020.01.011_b0035) 2010; 67 Dantzer (10.1016/j.bbi.2020.01.011_b0030) 2011; 36 Perlis (10.1016/j.bbi.2020.01.011_b0170) 2013; 74 Halaris (10.1016/j.bbi.2020.01.011_b0080) 2015; 66–67 Kohler (10.1016/j.bbi.2020.01.011_b0130) 2017; 135 Kaddurah-Daouk (10.1016/j.bbi.2020.01.011_b0120) 2011; 1 Coccurello (10.1016/j.bbi.2020.01.011_b0025) 2019; 372 Hiles (10.1016/j.bbi.2020.01.011_b0100) 2012; 26 Jha (10.1016/j.bbi.2020.01.011_b0115) 2017; 78 Frankle (10.1016/j.bbi.2020.01.011_b0050) 2018; 72 Howren (10.1016/j.bbi.2020.01.011_b0105) 2009; 71 Reus (10.1016/j.bbi.2020.01.011_b0190) 2015 Salomon (10.1016/j.bbi.2020.01.011_b0200) 1993; 8 Lamers (10.1016/j.bbi.2020.01.011_b0135) 2019; 85 Gupta (10.1016/j.bbi.2020.01.011_b0070) 2016; 21 Powell (10.1016/j.bbi.2020.01.011_b0180) 2013; 23 Jha (10.1016/j.bbi.2020.01.011_b0110) 2019; 113 Savitz (10.1016/j.bbi.2020.01.011_b0210) 2015; 40 Treadway (10.1016/j.bbi.2020.01.011_b0225) 2011; 35 McNicol (10.1016/j.bbi.2020.01.011_b0150) 1999; 95 Nie (10.1016/j.bbi.2020.01.011_b0165) 2018; 13 Meyer (10.1016/j.bbi.2020.01.011_b0155) 2001; 158 Liu (10.1016/j.bbi.2020.01.011_b0145) 2012; 139 Thase (10.1016/j.bbi.2020.01.011_b0220) 2001; 7 Pizzagalli (10.1016/j.bbi.2020.01.011_b0175) 2014; 10 Rush (10.1016/j.bbi.2020.01.011_b0195) 2006; 163 Stone (10.1016/j.bbi.2020.01.011_b0215) 2013; 34 Haapakoski (10.1016/j.bbi.2020.01.011_b0075) 2015; 49 Guidetti (10.1016/j.bbi.2020.01.011_b0065) 1999; 11 Uher (10.1016/j.bbi.2020.01.011_b0230) 2014; 171 Higashino (10.1016/j.bbi.2020.01.011_b0095) 2014; 729 Varghese (10.1016/j.bbi.2020.01.011_b0235) 2017; 1043 Cattaneo (10.1016/j.bbi.2020.01.011_b0015) 2016; 19 Wiedlocha (10.1016/j.bbi.2020.01.011_b0250) 2018; 80 Raison (10.1016/j.bbi.2020.01.011_b0185) 2009; 65 Felger (10.1016/j.bbi.2020.01.011_b0040) 2017; 42 Blardi (10.1016/j.bbi.2020.01.011_b0005) 2005; 25 Savitz (10.1016/j.bbi.2020.01.011_b0205) 2015; 52 Frank (10.1016/j.bbi.2020.01.011_b0045) 1991; 48 Block (10.1016/j.bbi.2020.01.011_b0010) 1993; 149 Wang (10.1016/j.bbi.2020.01.011_b0245) 2019; 1112 Gold (10.1016/j.bbi.2020.01.011_b0055) 2018; 10 Zhu (10.1016/j.bbi.2020.01.011_b0260) 2013; 8 Kocki (10.1016/j.bbi.2020.01.011_b0125) 2012; 119 Liu (10.1016/j.bbi.2020.01.011_b0140) 2018; 8 Greenberg (10.1016/j.bbi.2020.01.011_b0060) 2015; 76 Herr (10.1016/j.bbi.2020.01.011_b0090) 2017; 4 Walther (10.1016/j.bbi.2020.01.011_b0240) 2003; 299 |
| References_xml | – volume: 65 start-page: 296 year: 2009 end-page: 303 ident: b0185 article-title: Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression publication-title: Biol. Psychiatry – volume: 8 year: 2013 ident: b0260 article-title: Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder – possible role for methoxyindole pathway publication-title: PLoS ONE – volume: 25 start-page: 262 year: 2005 end-page: 266 ident: b0005 article-title: Activity of citalopram on adenosine and serotonin circulating levels in depressed patients publication-title: J. Clin. Psychopharmacol. – volume: 35 start-page: 537 year: 2011 end-page: 555 ident: b0225 article-title: Reconsidering anhedonia in depression: lessons from translational neuroscience publication-title: Neurosci. Biobehav. Rev. – volume: 113 start-page: 165 year: 2019 end-page: 171 ident: b0110 article-title: Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study publication-title: J. Psychiatr. Res. – volume: 19 start-page: 182 year: 2015 end-page: 187 ident: b0255 article-title: Anhedonia in depressed patients on treatment with selective serotonin reuptake inhibitor anti-depressant–A two-centered study in Malaysia publication-title: Int. J. Psychiatry Clin. Pract. – volume: 76 start-page: 155 year: 2015 end-page: 162 ident: b0060 article-title: The economic burden of adults with major depressive disorder in the United States (2005 and 2010) publication-title: J. Clin. Psychiatry – volume: 98 start-page: 143 year: 2007 end-page: 151 ident: b0160 article-title: Kynurenine pathway in major depression: evidence of impaired neuroprotection publication-title: J. Affect. Disord. – volume: 729 start-page: 86 year: 2014 end-page: 93 ident: b0095 article-title: Effects of acute and chronic administration of venlafaxine and desipramine on extracellular monoamine levels in the mouse prefrontal cortex and striatum publication-title: Eur. J. Pharmacol. – volume: 135 start-page: 373 year: 2017 end-page: 387 ident: b0130 article-title: Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies publication-title: Acta Psychiatr. Scand. – volume: 95 start-page: 1 year: 1999 end-page: 18 ident: b0150 article-title: Platelet dense granules: structure, function and implications for haemostasis publication-title: Thromb. Res. – volume: 67 start-page: 446 year: 2010 end-page: 457 ident: b0035 article-title: A meta-analysis of cytokines in major depression publication-title: Biol. Psychiatry – volume: 23 start-page: 1105 year: 2013 end-page: 1114 ident: b0180 article-title: Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response publication-title: Eur. Neuropsychopharmacol. – volume: 72 year: 2018 ident: b0050 article-title: An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxine publication-title: Synapse – volume: 52 start-page: 200 year: 2015 end-page: 211 ident: b0205 article-title: Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder publication-title: Psychoneuroendocrinology – volume: 11 start-page: 3857 year: 1999 end-page: 3863 ident: b0065 article-title: 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum publication-title: Eur. J. Neurosci. – volume: 372 year: 2019 ident: b0025 article-title: Anhedonia in depression symptomatology: Appetite dysregulation and defective brain reward processing publication-title: Behav. Brain Res. – volume: 163 start-page: 1905 year: 2006 end-page: 1917 ident: b0195 article-title: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report publication-title: Am. J. Psychiatry – volume: 1112 start-page: 24 year: 2019 end-page: 32 ident: b0245 article-title: LC-MS/MS-based quantification of tryptophan metabolites and neurotransmitters in the serum and brain of mice publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. – volume: 34 start-page: 136 year: 2013 end-page: 143 ident: b0215 article-title: An expanding range of targets for kynurenine metabolites of tryptophan publication-title: Trends Pharmacol. Sci. – volume: 40 start-page: 463 year: 2015 end-page: 471 ident: b0210 article-title: Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder publication-title: Neuropsychopharmacology – volume: 42 start-page: 216 year: 2017 end-page: 241 ident: b0040 article-title: Inflammation Effects on Motivation and Motor Activity: Role of Dopamine publication-title: Neuropsychopharmacology – volume: 10 start-page: 309 year: 2018 end-page: 325 ident: b0055 article-title: Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti-reward systems publication-title: Front. Biosci. (Schol. Ed.) – volume: 48 start-page: 851 year: 1991 end-page: 855 ident: b0045 article-title: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence publication-title: Arch. Gen. Psychiatry – volume: 49 start-page: 206 year: 2015 end-page: 215 ident: b0075 article-title: Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder publication-title: Brain Behav. Immun. – volume: 4 start-page: 48 year: 2017 ident: b0090 article-title: The Effects of Serotonin in Immune Cells publication-title: Front. Cardiovasc. Med. – volume: 71 start-page: 171 year: 2009 end-page: 186 ident: b0105 article-title: Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis publication-title: Psychosom. Med. – volume: 80 start-page: 217 year: 2018 end-page: 226 ident: b0250 article-title: Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis publication-title: Prog. Neuro-Psychopharmacol. Biol. Psychiatry – volume: 158 start-page: 1843 year: 2001 end-page: 1849 ident: b0155 article-title: Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study publication-title: Am. J. Psychiatry – volume: 1 year: 2011 ident: b0120 article-title: Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept publication-title: Transl. Psychiatry – volume: 78 start-page: 105 year: 2017 end-page: 113 ident: b0115 article-title: Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial publication-title: Psychoneuroendocrinology – volume: 171 start-page: 1278 year: 2014 end-page: 1286 ident: b0230 article-title: An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline publication-title: Am. J. Psychiatry – volume: 299 start-page: 76 year: 2003 ident: b0240 article-title: Synthesis of serotonin by a second tryptophan hydroxylase isoform publication-title: Science – volume: 7 start-page: S377 year: 2001 end-page: S385 ident: b0220 article-title: The clinical, psychosocial, and pharmacoeconomic ramifications of remission publication-title: Am. J. Manag. Care – volume: 26 start-page: 1180 year: 2012 end-page: 1188 ident: b0100 article-title: A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity publication-title: Brain Behav. Immun. – volume: 8 start-page: 10 year: 2018 ident: b0140 article-title: Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics publication-title: Transl. Psychiatry – volume: 66–67 start-page: 118 year: 2015 end-page: 126 ident: b0080 article-title: Does escitalopram reduce neurotoxicity in major depression? publication-title: J. Psychiatr. Res. – volume: 36 start-page: 426 year: 2011 end-page: 436 ident: b0030 article-title: Inflammation-associated depression: from serotonin to kynurenine publication-title: Psychoneuroendocrinology – volume: 85 start-page: 829 year: 2019 end-page: 837 ident: b0135 article-title: Longitudinal Association Between Depression and Inflammatory Markers: Results From the Netherlands Study of Depression and Anxiety publication-title: Biol. Psychiatry – volume: 38 start-page: 377 year: 2013 end-page: 385 ident: b0020 article-title: Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets' publication-title: Neuropsychopharmacology – volume: 36 start-page: 2452 year: 2011 end-page: 2459 ident: b0085 article-title: The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis publication-title: Neuropsychopharmacology – volume: 8 start-page: 41 year: 1993 end-page: 46 ident: b0200 article-title: The use of tryptophan depletion to evaluate central serotonin function in depression and other neuropsychiatric disorders publication-title: Int. Clin. Psychopharmacol. – volume: 139 start-page: 230 year: 2012 end-page: 239 ident: b0145 article-title: Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression publication-title: J. Affect. Disord. – volume: 19 year: 2016 ident: b0015 article-title: Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1-beta mRNA Levels Accurately Predict Treatment Response in Depressed Patients publication-title: Int. J. Neuropsychopharmacol. – volume: 21 start-page: 1717 year: 2016 end-page: 1725 ident: b0070 article-title: TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics publication-title: Mol. Psychiatry – volume: 74 start-page: 7 year: 2013 end-page: 14 ident: b0170 article-title: A clinical risk stratification tool for predicting treatment resistance in major depressive disorder publication-title: Biol. Psychiatry – start-page: 316 year: 2015 end-page: 328 ident: b0190 article-title: Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: evidences from animal and human studies publication-title: J. Psychiatry Res. – volume: 13 year: 2018 ident: b0165 article-title: Predictive modeling of treatment resistant depression using data from STAR*D and an independent clinical study publication-title: PLoS ONE – volume: 119 start-page: 235 year: 2012 end-page: 243 ident: b0125 article-title: New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio publication-title: J. Neural Transm. (Vienna) – volume: 10 start-page: 393 year: 2014 end-page: 423 ident: b0175 article-title: Depression, stress, and anhedonia: toward a synthesis and integrated model publication-title: Annu. Rev. Clin. Psychol. – volume: 149 start-page: 126 year: 1993 end-page: 128 ident: b0010 article-title: Quinolinic acid lesion of the striatum induces impairment in spatial learning and motor performance in rats publication-title: Neurosci. Lett. – volume: 1043 start-page: 65 year: 2017 end-page: 86 ident: b0235 article-title: The Role of Sex and Sex Hormones in Regulating Obesity-Induced Inflammation publication-title: Adv. Exp. Med. Biol. – volume: 35 start-page: 537 year: 2011 ident: 10.1016/j.bbi.2020.01.011_b0225 article-title: Reconsidering anhedonia in depression: lessons from translational neuroscience publication-title: Neurosci. Biobehav. Rev. doi: 10.1016/j.neubiorev.2010.06.006 – start-page: 316 year: 2015 ident: 10.1016/j.bbi.2020.01.011_b0190 article-title: Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: evidences from animal and human studies publication-title: J. Psychiatry Res. doi: 10.1016/j.jpsychires.2015.05.007 – volume: 95 start-page: 1 year: 1999 ident: 10.1016/j.bbi.2020.01.011_b0150 article-title: Platelet dense granules: structure, function and implications for haemostasis publication-title: Thromb. Res. doi: 10.1016/S0049-3848(99)00015-8 – volume: 78 start-page: 105 year: 2017 ident: 10.1016/j.bbi.2020.01.011_b0115 article-title: Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial publication-title: Psychoneuroendocrinology doi: 10.1016/j.psyneuen.2017.01.023 – volume: 25 start-page: 262 year: 2005 ident: 10.1016/j.bbi.2020.01.011_b0005 article-title: Activity of citalopram on adenosine and serotonin circulating levels in depressed patients publication-title: J. Clin. Psychopharmacol. doi: 10.1097/01.jcp.0000161500.58266.90 – volume: 34 start-page: 136 year: 2013 ident: 10.1016/j.bbi.2020.01.011_b0215 article-title: An expanding range of targets for kynurenine metabolites of tryptophan publication-title: Trends Pharmacol. Sci. doi: 10.1016/j.tips.2012.09.006 – volume: 149 start-page: 126 year: 1993 ident: 10.1016/j.bbi.2020.01.011_b0010 article-title: Quinolinic acid lesion of the striatum induces impairment in spatial learning and motor performance in rats publication-title: Neurosci. Lett. doi: 10.1016/0304-3940(93)90752-7 – volume: 19 year: 2016 ident: 10.1016/j.bbi.2020.01.011_b0015 article-title: Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1-beta mRNA Levels Accurately Predict Treatment Response in Depressed Patients publication-title: Int. J. Neuropsychopharmacol. doi: 10.1093/ijnp/pyw045 – volume: 119 start-page: 235 year: 2012 ident: 10.1016/j.bbi.2020.01.011_b0125 article-title: New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio publication-title: J. Neural Transm. (Vienna) doi: 10.1007/s00702-011-0668-8 – volume: 26 start-page: 1180 year: 2012 ident: 10.1016/j.bbi.2020.01.011_b0100 article-title: A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity publication-title: Brain Behav. Immun. doi: 10.1016/j.bbi.2012.06.001 – volume: 135 start-page: 373 year: 2017 ident: 10.1016/j.bbi.2020.01.011_b0130 article-title: Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies publication-title: Acta Psychiatr. Scand. doi: 10.1111/acps.12698 – volume: 36 start-page: 2452 year: 2011 ident: 10.1016/j.bbi.2020.01.011_b0085 article-title: The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis publication-title: Neuropsychopharmacology doi: 10.1038/npp.2011.132 – volume: 4 start-page: 48 year: 2017 ident: 10.1016/j.bbi.2020.01.011_b0090 article-title: The Effects of Serotonin in Immune Cells publication-title: Front. Cardiovasc. Med. doi: 10.3389/fcvm.2017.00048 – volume: 171 start-page: 1278 year: 2014 ident: 10.1016/j.bbi.2020.01.011_b0230 article-title: An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.2014.14010094 – volume: 1112 start-page: 24 year: 2019 ident: 10.1016/j.bbi.2020.01.011_b0245 article-title: LC-MS/MS-based quantification of tryptophan metabolites and neurotransmitters in the serum and brain of mice publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. doi: 10.1016/j.jchromb.2019.02.021 – volume: 10 start-page: 309 year: 2018 ident: 10.1016/j.bbi.2020.01.011_b0055 article-title: Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti-reward systems publication-title: Front. Biosci. (Schol. Ed.) doi: 10.2741/s518 – volume: 158 start-page: 1843 year: 2001 ident: 10.1016/j.bbi.2020.01.011_b0155 article-title: Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.158.11.1843 – volume: 74 start-page: 7 year: 2013 ident: 10.1016/j.bbi.2020.01.011_b0170 article-title: A clinical risk stratification tool for predicting treatment resistance in major depressive disorder publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2012.12.007 – volume: 8 start-page: 10 year: 2018 ident: 10.1016/j.bbi.2020.01.011_b0140 article-title: Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics publication-title: Transl. Psychiatry doi: 10.1038/s41398-017-0056-8 – volume: 65 start-page: 296 year: 2009 ident: 10.1016/j.bbi.2020.01.011_b0185 article-title: Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2008.08.010 – volume: 1043 start-page: 65 year: 2017 ident: 10.1016/j.bbi.2020.01.011_b0235 article-title: The Role of Sex and Sex Hormones in Regulating Obesity-Induced Inflammation publication-title: Adv. Exp. Med. Biol. doi: 10.1007/978-3-319-70178-3_5 – volume: 163 start-page: 1905 year: 2006 ident: 10.1016/j.bbi.2020.01.011_b0195 article-title: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report publication-title: Am. J. Psychiatry doi: 10.1176/ajp.2006.163.11.1905 – volume: 67 start-page: 446 year: 2010 ident: 10.1016/j.bbi.2020.01.011_b0035 article-title: A meta-analysis of cytokines in major depression publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2009.09.033 – volume: 19 start-page: 182 year: 2015 ident: 10.1016/j.bbi.2020.01.011_b0255 article-title: Anhedonia in depressed patients on treatment with selective serotonin reuptake inhibitor anti-depressant–A two-centered study in Malaysia publication-title: Int. J. Psychiatry Clin. Pract. doi: 10.3109/13651501.2015.1031139 – volume: 49 start-page: 206 year: 2015 ident: 10.1016/j.bbi.2020.01.011_b0075 article-title: Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder publication-title: Brain Behav. Immun. doi: 10.1016/j.bbi.2015.06.001 – volume: 85 start-page: 829 year: 2019 ident: 10.1016/j.bbi.2020.01.011_b0135 article-title: Longitudinal Association Between Depression and Inflammatory Markers: Results From the Netherlands Study of Depression and Anxiety publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2018.12.020 – volume: 1 year: 2011 ident: 10.1016/j.bbi.2020.01.011_b0120 article-title: Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept publication-title: Transl. Psychiatry doi: 10.1038/tp.2011.22 – volume: 98 start-page: 143 year: 2007 ident: 10.1016/j.bbi.2020.01.011_b0160 article-title: Kynurenine pathway in major depression: evidence of impaired neuroprotection publication-title: J. Affect. Disord. doi: 10.1016/j.jad.2006.07.013 – volume: 10 start-page: 393 year: 2014 ident: 10.1016/j.bbi.2020.01.011_b0175 article-title: Depression, stress, and anhedonia: toward a synthesis and integrated model publication-title: Annu. Rev. Clin. Psychol. doi: 10.1146/annurev-clinpsy-050212-185606 – volume: 299 start-page: 76 year: 2003 ident: 10.1016/j.bbi.2020.01.011_b0240 article-title: Synthesis of serotonin by a second tryptophan hydroxylase isoform publication-title: Science doi: 10.1126/science.1078197 – volume: 36 start-page: 426 year: 2011 ident: 10.1016/j.bbi.2020.01.011_b0030 article-title: Inflammation-associated depression: from serotonin to kynurenine publication-title: Psychoneuroendocrinology doi: 10.1016/j.psyneuen.2010.09.012 – volume: 52 start-page: 200 year: 2015 ident: 10.1016/j.bbi.2020.01.011_b0205 article-title: Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder publication-title: Psychoneuroendocrinology doi: 10.1016/j.psyneuen.2014.11.015 – volume: 8 start-page: 41 issue: Suppl 2 year: 1993 ident: 10.1016/j.bbi.2020.01.011_b0200 article-title: The use of tryptophan depletion to evaluate central serotonin function in depression and other neuropsychiatric disorders publication-title: Int. Clin. Psychopharmacol. doi: 10.1097/00004850-199311002-00006 – volume: 13 year: 2018 ident: 10.1016/j.bbi.2020.01.011_b0165 article-title: Predictive modeling of treatment resistant depression using data from STAR*D and an independent clinical study publication-title: PLoS ONE doi: 10.1371/journal.pone.0197268 – volume: 66–67 start-page: 118 year: 2015 ident: 10.1016/j.bbi.2020.01.011_b0080 article-title: Does escitalopram reduce neurotoxicity in major depression? publication-title: J. Psychiatr. Res. doi: 10.1016/j.jpsychires.2015.04.026 – volume: 40 start-page: 463 year: 2015 ident: 10.1016/j.bbi.2020.01.011_b0210 article-title: Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder publication-title: Neuropsychopharmacology doi: 10.1038/npp.2014.194 – volume: 23 start-page: 1105 year: 2013 ident: 10.1016/j.bbi.2020.01.011_b0180 article-title: Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response publication-title: Eur. Neuropsychopharmacol. doi: 10.1016/j.euroneuro.2012.09.009 – volume: 72 year: 2018 ident: 10.1016/j.bbi.2020.01.011_b0050 article-title: An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxine publication-title: Synapse doi: 10.1002/syn.22021 – volume: 48 start-page: 851 year: 1991 ident: 10.1016/j.bbi.2020.01.011_b0045 article-title: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence publication-title: Arch. Gen. Psychiatry doi: 10.1001/archpsyc.1991.01810330075011 – volume: 38 start-page: 377 year: 2013 ident: 10.1016/j.bbi.2020.01.011_b0020 article-title: Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets' publication-title: Neuropsychopharmacology doi: 10.1038/npp.2012.191 – volume: 42 start-page: 216 year: 2017 ident: 10.1016/j.bbi.2020.01.011_b0040 article-title: Inflammation Effects on Motivation and Motor Activity: Role of Dopamine publication-title: Neuropsychopharmacology doi: 10.1038/npp.2016.143 – volume: 113 start-page: 165 year: 2019 ident: 10.1016/j.bbi.2020.01.011_b0110 article-title: Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study publication-title: J. Psychiatr. Res. doi: 10.1016/j.jpsychires.2019.03.013 – volume: 76 start-page: 155 year: 2015 ident: 10.1016/j.bbi.2020.01.011_b0060 article-title: The economic burden of adults with major depressive disorder in the United States (2005 and 2010) publication-title: J. Clin. Psychiatry doi: 10.4088/JCP.14m09298 – volume: 729 start-page: 86 year: 2014 ident: 10.1016/j.bbi.2020.01.011_b0095 article-title: Effects of acute and chronic administration of venlafaxine and desipramine on extracellular monoamine levels in the mouse prefrontal cortex and striatum publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2014.02.012 – volume: 139 start-page: 230 year: 2012 ident: 10.1016/j.bbi.2020.01.011_b0145 article-title: Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression publication-title: J. Affect. Disord. doi: 10.1016/j.jad.2011.08.003 – volume: 372 year: 2019 ident: 10.1016/j.bbi.2020.01.011_b0025 article-title: Anhedonia in depression symptomatology: Appetite dysregulation and defective brain reward processing publication-title: Behav. Brain Res. doi: 10.1016/j.bbr.2019.112041 – volume: 71 start-page: 171 year: 2009 ident: 10.1016/j.bbi.2020.01.011_b0105 article-title: Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis publication-title: Psychosom. Med. doi: 10.1097/PSY.0b013e3181907c1b – volume: 8 year: 2013 ident: 10.1016/j.bbi.2020.01.011_b0260 article-title: Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder – possible role for methoxyindole pathway publication-title: PLoS ONE – volume: 80 start-page: 217 year: 2018 ident: 10.1016/j.bbi.2020.01.011_b0250 article-title: Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis publication-title: Prog. Neuro-Psychopharmacol. Biol. Psychiatry doi: 10.1016/j.pnpbp.2017.04.026 – volume: 7 start-page: S377 year: 2001 ident: 10.1016/j.bbi.2020.01.011_b0220 article-title: The clinical, psychosocial, and pharmacoeconomic ramifications of remission publication-title: Am. J. Manag. Care – volume: 11 start-page: 3857 year: 1999 ident: 10.1016/j.bbi.2020.01.011_b0065 article-title: 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum publication-title: Eur. J. Neurosci. doi: 10.1046/j.1460-9568.1999.00806.x – volume: 21 start-page: 1717 year: 2016 ident: 10.1016/j.bbi.2020.01.011_b0070 article-title: TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics publication-title: Mol. Psychiatry doi: 10.1038/mp.2016.6 |
| SSID | ssj0005318 |
| Score | 2.5001938 |
| Snippet | •Response to escitalopram was associated with higher baseline serotonin levels.•Response to escitalopram was associated with lower baseline Kyn/Trp ratio and... The response of patients with major depressive disorders (MDD) to antidepressant treatments have been shown to be affected by multiple factors, including... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 404 |
| SubjectTerms | Citalopram - therapeutic use Depressive Disorder, Major - drug therapy Desvenlafaxine Succinate Humans Kynurenic Acid Kynurenine Plasma Serotonin |
| Title | The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0889159119306622 https://dx.doi.org/10.1016/j.bbi.2020.01.011 https://www.ncbi.nlm.nih.gov/pubmed/31978524 https://www.proquest.com/docview/2345505806 |
| Volume | 87 |
| WOSCitedRecordID | wos000542965400093&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: ScienceDirect database customDbUrl: eissn: 1090-2139 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005318 issn: 0889-1591 databaseCode: AIEXJ dateStart: 19950301 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6DSFeEGxcymUyEtoDU6pcG_uxQh0XlQJaJ5WnyHFsqaNLujYt7b_gn_AXObbjtAU2xgNSFEWOnTg6X3yO7e-cg9BLmamY4LLtpGEQOKEMqcP8TDoB5xnY44RTE12_F_f7ZDiknxqNH9YXZjGO85wsl3TyX0UNZSBs5Tr7D-KuHwoFcA1ChzOIHc43FvzUUty2qFhgKF-wY-hEUapFWL1v8HWlPIVzZWuq5MTf2EollQZkKN_k47GiFM1qluWalT411Fqdd0OAFlVrQJMpM_k2MjGDIXTMJFvaXfs6hBIzMQtsdABLHh1pN5WyXt8_netqX-a1oa1CTZWGEshWay7AAHrPTertN8oXbFHYOz1d-BlU8yV86-nm8gbMZS0V1o7ILnUd3zMRj1riD2XVMF7pbTMOhyan8W_6wSxVnLfSdNRSb9MhW6vRfisWd_9jcnLW6yWD7nBwNLl0VJoytZ1f5WzZQXt-HFEYRvc677rD92tWkVlSrntoN9I1pfCXt15lCl011dEmz-AeulvNVXDHYOw-aoh8Hx10clYWFyt8hDV7WG_L7KPbHyqSxgH6DgjEmwjEFQKxQSCuEYhB9HiNQFwhEK8RiA0CdUVAIK4RiC0CcVngTQTqqtsIfIDOTrqD12-dKvGHw8H-LJ2IeilhYJtKGvmceZ6Aeb6QXMSStNMoDkmbBJ4nA0GYzGTAQKnADZdKrqLtpsFDtJsXuXiMMEwQKPfb1IdHwGVGwjANOOUE5mkpIaKJXCuDhFdR8VVylnFi6Y_nCYgtUWJLXA8Or4le1U0mJiTMdZV9K9jE-jqDdk4AkNc1CutGlSFsDNy_NXthkZOAklA7fywXxXyW-IEKXhARt91Ejwyk6q6DDo5J5IdPbtD6Kbqz_kefod1yOhfP0S2-KEez6SHaiYfksPojfgJwAu4j |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+relationship+between+plasma+serotonin+and+kynurenine+pathway+metabolite+levels+and+the+treatment+response+to+escitalopram+and+desvenlafaxine&rft.jtitle=Brain%2C+behavior%2C+and+immunity&rft.au=Sun%2C+Yu&rft.au=Drevets%2C+Wayne&rft.au=Turecki%2C+Gustavo&rft.au=Li%2C+Qingqin+S&rft.date=2020-07-01&rft.issn=1090-2139&rft.eissn=1090-2139&rft.volume=87&rft.spage=404&rft_id=info:doi/10.1016%2Fj.bbi.2020.01.011&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0889-1591&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0889-1591&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0889-1591&client=summon |